ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SCLP Scancell Holdings Plc

9.60
0.00 (0.00%)
Last Updated: 08:00:21
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.60 9.40 9.80 9.60 9.38 9.60 148,854 08:00:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.44 89.07M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.60p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £89.07 million. Scancell has a price to earnings ratio (PE ratio) of -7.44.

Scancell Share Discussion Threads

Showing 15651 to 15672 of 65950 messages
Chat Pages: Latest  634  633  632  631  630  629  628  627  626  625  624  623  Older
DateSubjectAuthorDiscuss
20/5/2018
14:38
Hi Inan. I'll respond.

DRD - your diet of BIG BUCKETS, custard and Herbaloaf needs reconsideration ?
Loz seems to be your Hero ? Hard to twig that one . . .

You claim to be a 'custardian' of the BB. Hilarious.
And KFC a restaurant ? Sweet Lord !

Are you an 'APP' ? Spread by the dastardly Loz ?

You're just having 'fun' aren't you ? If not - lighten up and atb.

torquayfan
20/5/2018
14:16
i wait to see how many respond to your posts Dobson ... i think you would get more chicken legs in your bucket than posters

the interesting question is "Loz freebies", he sold his last tranche to buy wood, not hold that profit as freebies ...

any way best of luck following loz, by the way you bought before the OO which was not loz's policy

but your smart ... i think

inanaco
20/5/2018
14:07
LOZ great to see you post how you CAN achieve Freebies by Simple buying and selling.Well done on this.Just back from BIG bucket Meal at my favourite restaurant.
Contrast clear concise POSTS on here TOday discussing science and commercial stuff in balanced way after me,Lol and others raised the Bar as Custardians of the board.
Thanks to Timbo,Bermuda,goosey and contrast with other place where baNANA is right for CONce.He says the board is diminished and only a dwindling number of posters while here is BOOMing and the share price will hopefully go UP UP and AWAY so I Can treat family to a BANK holiday slap,UP.
What baNANA forgot to say is which Board does he post ON and IS the DIMinishing board related TO his DIMwitted posting.
Is there a Link and is it the mixing ONE.
Guffaw

drdobson1
20/5/2018
13:18
Timbo,

Thanks, posts crossed.

Understand now and makes sense. Started reading up a bit on DNA vaccine delivery systems when they mentioned nanovesicle delivery for SCIB2. Things certainly seemed to have moved on.

bermudashorts
20/5/2018
13:09
Inanaco - yes, your last sentence was what I was getting at.

Gooosed - thanks for link. Note his vision of the future - tailoring treatment to patient's tumours. Very much along the lines of LD's Grand Challenge vision of personalised vaccines and developing a template to allow oncologists to select the appropriate vaccine for each patient.

bermudashorts
20/5/2018
13:08
>>BS

LD stated at the 2015 AGM that the optimal dose in humans would be 20mg and patients would probably be reluctant to have anymore than two injections


The problem with going above 8mg, is that higher doses would require higher concentrations and higher concentrations would lead to higher (unacceptable) viscosities. The new nano-vesicle tech (for SCIB2) should get over this problem as it will be administered in a larger volume (via sub-cutaneous or IV)


RG confirmed that the new Ichor device would not overcome the viscosity problem (and improvements were largely cosmetic) at the July 2016 Proactive meeting:

timbo003
20/5/2018
12:49
Its more likely the ring of field effective that opens the cell membranes around the injection site has a limit as the Voltage and amps are critical so that cell damage cannot occur, then a limit of size is reached that is effective, and the "spread" of DNA from the injection site would also have limits of how they can get into a cell while this membrane is held open by the electric field.
inanaco
20/5/2018
12:02
super,

Yes, it's clearly not a pleasant procedure so not good to have two shots but assume there must be a reason why it can't handle a bigger dose - perhaps down to simple biology? Is there a max that cells within a specified area can take?? I don't know, perhaps someone else does.

If not due to scientific reason then it will be interesting to see whether that's been rectified with the new 2nd generation device which Scancell will be using for the combination trial.

bermudashorts
20/5/2018
11:33
I most dislike the fact that it can't deliver the optimum dose. Whose interests come first - Ichor's owners, or cancer patients?
supernumerary
20/5/2018
11:04
Timbo,

Thanks for explanation. Knew you weren't keen on the device but was interested in your thoughts on the agreement itself. Thanks also for link to slides.

bermudashorts
20/5/2018
10:55
The slides from Wednesday’s ShareSoc presentation are now available here:



>>>BS (post # 15679)

I don’t like the Ichor device for numerous reasons, first and foremost because patients do not like it and there are probably better technologies available which do not involve electrocuting the patient. However, leaving those issues aside, I also do not like the deal they struck with Scancell concerning SCIB1 and any other similar melanoma vaccines, thoughts are as follows:

We do not know the size of the royalties or milestone payments, so I cannot comment on that, but I do know that there were just too many “in the money” options that went with the deal (5% of the issued share capital, for just one product):


This would not be such an issue if Ichor were a cash generating established tech company, who wished to exercise the options to take a long term strategic stake in Scancell. However, unfortunately they do not fit that description, instead they are a cash hungry, pre-revenue tech company who are most likely to exercise the options and sell the resulting shares at the earliest opportunity in order to provide short term working capital.

timbo003
19/5/2018
12:49
"MIFFED" -
"so you start your campaign with slagging off scancell for years and missed the bottom"
The obvious PAIN *WE ALL* see resulting from the FAILURE to trHYPE SCAM the S P up, is, ONCE AGAIN distorted to 'invent' LIES, FALSE CLAIMS in order to 'mislead others' and 'soothe YOUR fractured EGO'...Whilst more competent 'players' step-in to 'take the cream' from under YOUR nose.
*WE ALL* KNOW, that, in TRUTH,... I have NEVER, or CAN be shown to HAVE EVER been =
..." slagging off scancell for years "
I HAVE however, successfully PROVEN to 'open-minded punters' = YOUR, and YOUR CLUB'S misleading efforts to 'invent' LIES, FALSE CLAIMS in order to 'mislead others' .
AND
Highlight, YOUR very costly FAILURE, which has allowed more intelligent 'players' to 'enjoy the REALITY'
154

the real lozan
19/5/2018
11:50
Examples =
Lets say one bought £1,000 worth of shares in Feb { Which one COULD} at 10p =
10,000 shares
Then SOLD 10,000 in Mar {Which one COULD} at 18p =
£1,800
Then, one re-invested the £1,800 at the end of MAR {Which one COULD} at 13.25p =
circa 13,500 shares.
Then SOLD 13,500 in mid April {Which one COULD} at 17.50p =
£2,362.50p
Then, one bought back in ..KNOWING that "FUNDING WAS always an "On the CARDS " ISSUE", when the *EXPECTED* OO WAS finally announced... at 12p =
circa 19,700 shares
.
NOW at say 15p, the INITIAL £1,000, stands at = a holding worth £2,955
.
OR
One COULD have been BUY,BUY,BUYING... and urging others to do so... at 19p, just prior to the FULLY EXPECTED 'fund raising'
AND
Having to 'STUM-UP' more cash to cover HIS trHYPE induced LOSSES + dilution.
.....
Little wonder, the "ONE VIEW ONLY", "BUY and hold", DYE HARD trHYPE 'GROUP' are, and, show, via their FAILINGS, 'miffed' at those who KNOW = How to, by intelligent/ common sense, REALLY 'Play the game'.
PROFITABLY

the real lozan
19/5/2018
11:39
So its a competition is it loz .. who can make the most money ?

so you start your campaign with slagging off scancell for years and missed the bottom

so the interesting bit would be How many do you have and what price ?

many have declared ..C7 booked his profit already, even Mr W declares he kept 25,000

or is it your little secret ? . Ie. the truth you have non

inanaco
19/5/2018
11:08
The "Define a diehard Inanaco? " spat -
Most amusing to see the LOSS BOSS try to 'invent' some kind of 'virtue' for 'a FLOCK of long termers' who have been - Unlike the WISER, more ASTUTE - 'SLOW to react' to the CLEAR opportunities, from which to MAKE 'n' TAKE ....PROFITS.
It is quite easy to "Define a diehard Inanaco? "
They are the ones who, by swallowing, and blindly following/supporting the trHYPE.. are STILL = DYE hard...in the RED.
It must be VERY frustrating for the GROUP to watch the WISER, more ASTUTE... and others - who have 'Taken on board' the observations of 'Alternative Views'... now being able to 'take advantage and STEP-IN to take 'the cream'.
The 'better players' are already 'IN PROFIT'... whilst most DYE HARDS are still 'stained RED' by their COSTLY 'blinkered / servile' trHYPE mentality.

the real lozan
18/5/2018
16:02
Goosey.
Just like I have called it explain the science in a simple way to appeal to those amongst us NOT blest as BOFFINS or BUFFOONS on some cases.
Reading other Board that Chelsea 7 is right baNANA only mentioned sone big holders BUT sone on here like him and ME may not have the BIG holdings BUT is a BIG %age of our WEALTH.

drdobson1
18/5/2018
15:26
From crumbs on LSE SCLP bb ".... but meantime yeah get those vids done explaining where scancells tech fits in the field and therefore the market."

This idea has been put to both RG (who added it to the to do list) and then Holloway who recently confirmed "time permitting I would like to pursue this further."

The suggestion was an animation style presentation which would ideally have a voice over covering the verbal explanation of the tech by Lindy. Another twitter group poster pointed out that UoN have the facilities within their media course set up. One for each platform perhaps.

An example might be akin to those produced by MSK or in the style of a sponsored prize winner (keeping costs down) :

gooosed
17/5/2018
14:55
Timbo,

If you're around still, going back to your comment on the terms of the Ichor agreement, what didn't you like? I believe the existing agreement expires in July so they'll need to extend again for the SCIB1 trial.

bermudashorts
17/5/2018
11:42
Key takeaway for me is he said they now have the capital to drive this forward into the clinicFound the we are not in the business of curing mice,but humans amusing.The co has demonstrated it can raise capital and that builds kudos with both the market and any potential partners. The US is where the focus will switch and US funds can be very aggressive if they like a company.The 35p area will be an interesting initial target.Gla
j777j
17/5/2018
10:16
Thanks timbo.
gooosed
17/5/2018
09:58
If anyone can open that up

hxxps://pubs.acs.org/doi/ipdf/10.1021/acsami.6b14132

We report a new and general method, in situ growth, for designing self-assembled protein–polymer nanovesicles for intracellular protein delivery.In situ polymerization of a water-soluble monomer from a protein attached with a polymerization initiator yields amphiphilic protein conjugates of a water-insoluble polymer. These conjugates can in situ self-assemble into nanostructures with tunable morphologies from spheres to vesicles. Interestingly, an exogenous protein can be in situ encapsulated inside protein–polymer nanovesicles for enhanced intracellular protein delivery. The in situ growth method may open up new opportunities for designing a variety of self-assembled protein–polymer nanostructures tailored to specific applications.

maybe we look to China ...

inanaco
17/5/2018
09:52
Thanks Timbo.
So was that you asking the question about 'gruesome' Ichor ?
Hopefully Scancell can arrange a deal to use 'nanovesicles' before too long !
ATB

torquayfan
Chat Pages: Latest  634  633  632  631  630  629  628  627  626  625  624  623  Older

Your Recent History

Delayed Upgrade Clock